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Purpose: Asthma is a disease of increasing worldwide impor-
tance that calls for new investigative methods. Ex vivo lung
tissue is being increasingly used to study functional respiratory
parameters independent of confounding systemic considera-
tions but also to reduce animal numbers and associated
research costs. In this work, a straightforward laboratory
method is advanced to probe dynamic changes in gas inhala-
tion patterns by using an ex vivo small animal ovalbumin
(OVA) model of human asthma.
Methods: Hyperpolarized (hp) 129Xe was actively inhaled by
the excised lungs exposed to a constant pressure differential
that mimicked negative pleural cavity pressure. The method
enabled hp 129Xe MRI of airway responsiveness to intravenous
methacholine (MCh) and airway challenge reversal through
salbutamol.
Results: Significant differences were demonstrated between
control and OVA challenged animals on global lung hp 129Xe
gas inhalation with P<0.05 at MCh dosages above 460 mg.
Spatial mapping of the regional hp gas distribution revealed an
approximately three-fold increase in heterogeneity for the
asthma model organs.
Conclusion: The experimental results from this proof of con-
cept work suggest that the ex vivo hp noble gas imaging
arrangement and the applied image analysis methodology
may be useful as an adjunct to current diagnostic techniques.
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INTRODUCTION
New insights into the pathophysiology of asthma, a
chronic inflammatory disorder of the airways (1), have
been provided over the last 20–30 years by a variety of
molecular and biomedical techniques (2,3), some of
which, such as monoclonal antibody technologies (4),
have resulted in new treatments. Unfortunately, despite
this progress, rates of asthma continue to rise with
the disease becoming of increasing importance world-
wide (5–7). The advancement of new methods that pro-
vide a better understanding of the disease and that
facilitate drug development studies is, therefore, urgently
required.
Rodent models of asthma are widely used to study the
disease (8,9) and have allowed for advances in the
understanding and treatment of the condition. For exam-
ple, the development of inhaled corticosteroid and bron-
chodilator medications and the need for combination
therapies have resulted from such studies (10–13). There
are several animal models of asthma currently in use
that display many features of human asthma (14–17)
with the ovalbumin (OVA) model of allergic asthma one
of the best characterized (18). Although rodent responses
include high IgE titers, similar to human disease, (19,20),
levels of airway hyper-responsiveness (AHR) are often
low when measured by conventional respiratory
measurements (18,21). The imaging methodologies of
ultrashort echo time (UTE) MRI and microcomputed
tomography have since been used to study airway
inflammation (22) and remodeling (23), respectively.
Hyperpolarized (hp) noble gas MRI, however, has the
ability to provide information on lung responses with
direct visualization of regional changes in ventilation
(24–27) potentially allowing for the sensitive detection of
AHR.
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There has been a move toward the use of ex vivo lung
tissue to investigate lung responses in health and disease
in an effort to limit research costs and impact the “3Rs”
of reducing animal numbers, replacing animal experi-
ments by alternative techniques or refining procedures
to limit animal suffering (28,29). An additional benefit of
ex vivo experiments is the ability to study physiological
and functional respiratory parameters independent of
confounding systemic variables. Examples of such varia-
bles include: alterations in respiratory rate and volumes;
anesthetic considerations, coupled with the effects of
bronchoactive substances on other organ systems; and
nonpulmonary compensation mechanisms (28,30,31). In
light of this, precision-cut lung slice (PCLS) models in
particular are gaining increasing acceptance as a method
to study lung responses (32–37). While there is much
benefit to be derived from PCLS models there are notable
problems in terms of the removal of the intact circulation
and bronchial tree, resulting in a nonphysiological deliv-
ery of compounds to the lung (28).
As an alternative to the PCLS methodology, whole
organ ex vivo models may be used (30,31,38), benefiting
from the absence of systemic influences while retaining
delivery methods for compounds more akin to the in vivo
situation (39,40) and allowing for the study of whole
organ factors such as hyperventilation (41). Furthermore,
previous work has explored airway responsiveness in the
ex vivo mouse lung using conventional respiratory meas-
urements (42). The purpose of this work was, therefore, to
investigate differences in gas inhalation patterns during
repeated intravenous challenges with the muscarinic ago-
nist, methacholine, using the previously developed ex
vivo hp 129Xe MRI methodology (43).
METHODS
Model Characterization and Preparation for Ex Vivo
hp 129Xe MRI
Animals
The University of Nottingham Ethical Review Committee
approved the study, which was carried out in accordance
with the UK Home Office Animals (Scientific Procedures)
Act 1986. Male Brown-Norway rats (150–199 g; n¼ 18)
were purchased from Charles River Ltd (Margate, UK) and
housed in the Biomedical Services Unit, University of
Nottingham for at least 7 days before commencement of
the study. Animals had free access to food and water.
Ovalbumin Induced Asthma
Animals were sensitized by intraperitoneal injections of
2 mg of ovalbumin (OVA) with 200 mg of aluminum
hydroxide (Alum) in 1 mL on day 0 and day 14 (44) (see
Figure 1a). Animals were challenged with increasing
concentrations of intratracheal (i.t.) OVA in 300 mL of
sterile phosphate buffered saline (PBS, Sigma-Aldrich
Ltd, Gillingham, UK), or PBS only control, on days 21
and 23, administered under inhaled general anesthesia
(4% isofluorane 96% medical grade oxygen at a flow rate
of 2L/min for 3–4 min). On day 24, animals were
weighed and euthanized by overdose of sodium pento-
barbital (Sigma-Aldrich Ltd, Gillingham, UK).
Preparation for Ex Vivo hp 129Xe MRI
Lungs for ex vivo hp 129Xe imaging had a cannula
inserted into the caudal vena cava to allow flushing of the
pulmonary circulation with heparin 100 IU/mL (Wock-
hardt UK Ltd, Wrexham, UK) in 20 mL 0.9% saline solu-
tion followed by 20 mL of PBS to remove residual blood
from the pulmonary circulation. The heart and lungs were
removed en masse. A polytetrafluorethylene (PTFE)
adapter tube was inserted 5–10 mm above the carina and
sutured into place. The heart and lungs were suspended
in Hartmann’s solution (Baxter Healthcare Ltd, Thetford,
UK) in the custom-built ventilation chamber with the tra-
chea pointing downward as detailed previously (43). The
ex vivo lungs were repeatedly inflated with 5–6 mL of
room air to check for gas leaks. The lungs were chilled to
FIG. 1. Sensitization and challenge protocol with typical light
microscopy images of control and OVA challenged lungs. a: All
rats were sensitized with intrapertioneal (IP) injections of 2 mg of
ovalbumin and 200 mg of aluminum hydroxide (Alum) on day 0
and day 14 with subsequent intratracheal (IT) challenges on days
21 and 23 of either 300 mL of sterile PBS (control animals) or 300
mL of OVA (500 mg/250 mg of OVA) with the same OVA dose on
each challenge. Animals were killed on day 24 for either BAL/his-
tology or ex vivo hp 129Xe MRI. b: Light microscopy image from (i)
control (PBS challenged) lung and (ii) 500-mg OVA challenged
lung. Note the clear airspaces and thin bronchial walls of the large
airways (arrow) in the control lung in contrast to the marked
increase in cellular infiltrate particularly around the large airways
(arrow) in the OVA challenged lung.
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278 K for transportation to the imaging facility. After
transportation, the lungs were passively warmed to ambi-
ent temperature before imaging. The time from harvest to
MR imaging was no more than 5 h.
Of all animals enrolled in the study, six rats were
treated with 500 mg OVA i.t., three rats were treated
with 250 mg OVA i.t. and nine control rats were treated
using i.t. D-PBS. Of these animals, three 500 mg OVA
and three D-PBS control rats were used solely for BAL
and histological analysis. During the hp 129Xe experi-
ments, one 250-mg OVA treated rat lung proved unsuit-
able for imaging due to gas leakage with three control
lungs suffering from similar issues, therefore, also being
rejected for ex vivo hp 129Xe MRI.
Histology
Lungs were inflated with 10% formalin-saline solution
(Sigma-Aldrich Ltd, Gillingham, UK) at a pressure of
25 cm of H2O ( 2.5 kPa) for 24–48 h and paraffin-wax
embedded. Five-micron sections were stained with
hematoxylin and eosin (H&E). The resulting H&E stained
histological sections were visualized using a Nikon
Eclipse 90i microscope (Nikon Corporation, Tokyo,
Japan) with NIS Elements Ar image analysis software for
image capture (v.3.2, Nikon Corporation, Tokyo, Japan).
Bronchoalveolar Lavage
A separate group of control and OVA challenged rats
that were not subjected to MR imaging had bronchoal-
veolar lavage (BAL) performed post mortem with 1 mL
of PBS instilled i.t. before subsequent removal. BAL sam-
ples were centrifuged at 231  g (1500 rpm) for 5 min
with the resulting cell pellet resuspended in 1 mL of
PBS. Total BAL cell count was performed with a Sceptor
automated cell counter (Millipore, UK). BAL cells were
then centrifuged at 100  g onto slides and stained using
Diff Quik Romanowski stain (Fisher Scientific, UK). The
% of differential inflammatory cells was determined by
counting 100 cells using a light microscope at 40
magnification.
129Xe spin exchange optical pumping, compression and
transfer
Hp 129Xe was produced in batch mode using spin
exchange optical pumping (SEOP) (45,46) of a gas mix-
ture containing 25% Xe (enriched to 83% 129Xe, Nova
Gas Technologies, Charleston, SC, USA) and 75% nitro-
gen (N2, 99.999% pure, Air Liquide, Coleshill, UK).
SEOP was performed at 40–60 kPa followed by hp gas
delivery to the lung as reported in ref. 47. The hp Xenon
was not cryogenically separated before delivery to the
excised lungs for inhalation. The spin polarization was
approximately P¼ 40% that, factoring in the four-fold
gas dilution, provided an “apparent” spin polarization of
Papp¼10% (48).
Hp Gas Inhalation
The ventilation chamber with the ex vivo lungs was
placed inside the bore of the superconducting magnet
and held at a constant temperature of 293 K. Active
inflation of the lung was accomplished by pulling to a
ventilation syringe volume (Vs) of 6 mL. Corresponding
inhaled volumes (Vi) were measured separately using a
water displacement technique on gas exhalation listed in
Table 1. To limit potential gas trapping, the ex vivo
lungs were deflated over 30–60 s from Vs¼6 mL to max-
imum exhalation (Vs¼ 0 mL) as reported elsewhere
(49,50) before hp 129Xe inhalation.
Bronchoconstriction and Reversal
Animals used for hp 129Xe MRI experiments had the
catheter used for flushing of the pulmonary circulation
retained. The cranial vena cava was ligated to ensure
drug delivery to the pulmonary circulation. The cannula
in the caudal vena cava was sutured into place and
attached to 1.6-mm outer diameter perfluoroalkoxy (PFA)
tubing for administration of drugs to the pulmonary cir-
culation as detailed in previous work (43). Excess fluid
was removed to keep the fluid level within the ventila-
tion chamber constant during the imaging experiments.
In an attempt to satisfy tissue metabolic demands, the
lungs were ventilated 8–10 times with the 100% oxygen
immediately after imaging followed by purging the lungs
and transfer line with N2 before MCh (with Hartmann’s
solution) and hp 129Xe delivery. This resulted in the
lungs being held in an anoxic condition for less than 3–4
min.
Initial hp 129Xe MR imaging was repeatedly performed
at baseline to ensure reproducibility of hp gas inhalation
with multiple images (minimum of two) acquired and
visually inspected to ensure a stable reference point for
comparison of later image data on increasing MCh dos-
ages. Furthermore, 4.5 mL of Hartmann’s solution was
delivered at a rate of 1–2 mL/min before bronchoprovo-
cative challenges to ensure there were no significant
changes on hp 129Xe MRI after fluid administration to
the lung.
Bronchoconstriction was achieved by delivering meth-
acholine (MCh, Sigma-Aldrich Ltd, Gillingham, UK)
through the pulmonary circulation as detailed previously
(43). Increasing doses of 10, 25, 50, 75, 100, 200, and 400
mg of MCh dissolved in 1 mL of 0.9% saline solution
Table 1
Demographic Data from Subjects Used for hp 129Xe Imaginga
Identifier
OVA
challenge
dose (mg)
Rat
weight
(g)
Inhaled
volume
Vi (mL)
CONTROL C.1 N/A 259 4.26 0.3
C.2 N/A 262 5.06 0.4
C.3 N/A 218 5.26 0.4
OVA
CHALLENGED
OVA.1 500 252 4.96 0.3
OVA.2 500 254 4.96 0.4
OVA.3 500 270 4.66 0.1
OVA.4 250 223 5.16 0.1
OVA.5 250 210 4.86 0.1
Summary of rat weights at the time of organ harvest, ovalbumin
(OVA) dosages, and inhaled volumes (Vi)6 standard deviation cor-
responding to inflation (syringe) volume Vs¼6 mL. Note all control
animals received 300 mL sterile D-PBS on airway challenges.
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followed by a 3.5-mL bolus of Hartmann’s solution at a
rate of 1–2 mL/min were delivered before sequential hp
129Xe imaging experiments. Each image was acquired on
a separate inhalation of hp 129Xe. The maximum cumula-
tive dose of MCh delivered to each set of excised lungs
was 860 mg. The bolus of Hartmann’s solution following
the MCh was to ensure complete drug delivery to the
lung by flushing out the dead volume in the delivery
system. Reversal of bronchoconstriction was attempted
by flushing the lungs with 30–50 mL of Hartmann’s solu-
tion and 1000–1500 mg of salbutamol (Allen and Han-
bury’s Ltd, Middlesex, UK) in 1.0–1.5 mL at a rate of 1–
2 mL/min. The monitored airway pressure during inhala-
tion was kept constant between successive images using
the pressure value at baseline for an inflation syringe
volume Vs¼6 mL. Typical airway pressures recorded
during inhalation in control and OVA challenged lungs
were 2.2–2.6 kPa (22–26 cm H2O) and 2.5–3.0 kPa (25–
30 cm H2O), respectively.
MRI Protocol
MR imaging experiments were performed using a 9.4
Tesla (T) vertical bore Bruker Avance III microimaging
system (Bruker Corporation, Billerica, MA). A custom-
built 25 mm low-pass birdcage volume coil tuned to the
resonance frequency of 129Xe gas (110.69 MHz) was used
in all experiments. Images were acquired using a modi-
fied variable flip angle (VFA) FLASH gradient echo
pulse sequence (51). Rectangular pulses of 134 ms
(1.8 KHz bandwidth) and sinc-shaped pulses of 1000 ms
(240 Hz excitation bandwidth) at variable power levels
were used for non–slice-selective and slice-selective
image acquisitions (echo time¼1.27 ms; repetition time-
¼ 67.5 ms). All coronal images were acquired in 128 
64 image matrices with a field of view (FOV) of 47.3 mm
and 31.5 mm in the read and phase-encoding directions,
respectively. Total acquisition time was 4.38 s. At a fre-
quency domain spectral bandwidth of 50 KHz, this rela-
tively long acquisition period was solely due to
limitations of the custom built coil to prevent coil heat-
ing and arcing. Note that the long acquisition time may
have caused some diffusive attenuation and image blur-
ring. Signal-to-noise ratio (SNR) values from non–slice-
selective hp 129Xe images were 70 and 50 at baseline
in the healthy and OVA treated lungs, respectively.
Slice-selective imaging experiments were performed
where a single 4 mm central slice was acquired with a
resulting nominal resolution of 0.37  0.49  4 mm3.
SNR values from the slice selective images were 30
and 20 for the healthy and OVA treated lungs,
respectively.
Image Reconstruction and Analysis
Images were processed and reconstructed in Prospa
(v.3.06, Magritek, Wellington, New Zealand) with a sine-
bell squared window function applied to the raw data
before two-dimensional (2D) Fourier transformation. The
2D image data were then exported for analysis in IGOR
Pro (v.6.01, Wavemetrics, Lake Oswego, OR). Calculation
of whole lung SNR values were made by thresholding
the image matrix with the lower threshold derived from
the mean signal intensity plus three standard deviations
obtained from a 10  10 voxel region randomly selected
outside the lung region within the image limits.
Measurement of Global Reduction in hp 129Xe Inhalation
As a measure of the reduction in global hp 129Xe signal
across the whole lung, the normalized global signal
intensity, GS , was obtained for all steps on the MCh
challenge protocol (and after salbutamol reversal) by
dividing the sum of all k voxel values
Pi¼k
i Mi across
each image by the sum of all k voxel values of the base-
line image
Pi¼k
i Bi:
GS ¼
Xi¼k
i
Mi=
Xi¼k
i
Bi [1]
where the subscript i denotes the voxel number. To
ensure that no fluctuation in the background noise
would affect the normalized global signal intensity, the
noise levels from 10  10 voxel regions far-removed
from the lung were monitored, with mean noise values
calculated and compared between images in the MCh
challenge sequence. Mean noise values were seen to be
consistent between subsequent images with fluctuation
of <20%.
Visualization of Changes in Regional hp 129Xe Inhalation
Caused by MCh Challenges and Reversal
Maps of absolute intensity difference, DAi , were calcu-
lated by subtracting the baseline image data from data on
increasing MCh dosages (Mi) similar to the method
reported by Mistry et al (52):
DAi ¼ Mi  Bi [2]
In analogy, difference maps on reversal were calcu-
lated using image data of the 400 mg MCh dose (860 mg
cumulative dose MCh) for subtraction from the image
acquired on reversal.
Maps of relative intensity difference, DRi, were
obtained by dividing each voxel value Mi by the mean
voxel intensity k1
Pi¼k
i Mi resulting in the relative inten-
sity data of the respective MCh challenge. The relative
intensity data of the baseline image is then subtracted
and the resulting expression is further scaled by the
global signal intensity, GS:
DRi ¼ Mi
k-1
Pi¼k
i
Mi
-
Bi
k-1
Pi¼k
i
Bi
0
BBB@
1
CCCA
100%
GS
[3]
with k as the total number of voxels. In analogy, rela-
tive intensity difference maps for the reversal were
obtained by subtracting the 400 mg dose of MCh (860
mg cumulative dose MCh) data from the salbutamol
reversal data.
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Statistical Analysis
Statistical analysis was performed using GraphPad
PRISM (v.6.0, GraphPad Software Inc., La Jolla, CA).
Mean total inflammatory cell counts and differences in
SNR values were compared using the student’s t-test.
Bland-Altman analysis was performed to compare % dif-
ference between the nonslice and slice-selective values
of normalized global signal intensity. Comparison of the
dose response curves between the control and OVA chal-
lenged groups was performed using a two-way analysis
of variance with the Bonferroni test for post hoc compar-
ison between cumulative MCh dosages (as compared
with baseline measurements). Probability values P< 0.05
were deemed to be significant.
RESULTS
OVA Sensitized and Challenged Rats Develop Eosinophilic
Airways Disease
Qualitative comparison of histological lung sections
revealed notable thickening of the bronchial epithelium
and accumulation of inflammatory cells in OVA chal-
lenged rats when compared with control animals (Fig.
1). Quantitative analysis of BAL inflammatory cells dem-
onstrated that total inflammatory cells present in BAL
samples were significantly increased in OVA challenged
animals (P¼ 0.03; Figure 2a) and differential cellular
analysis confirmed that the increase was predominantly
in eosinophils (Fig. 2b) in line with previous studies
(19,53,54).
Dynamic Changes in hp 129Xe Gas Distribution on
Increasing Dosages MCh and Salbutamol Reversal
Images at key points of the MCh challenge protocol from
control and OVA challenged lungs demonstrating the
differences in regional gas distribution and inhalation
volume for increasing MCh doses are displayed in Figure
3 (full dataset in Appendix 1 in the Supporting Informa-
tion, which is available online). The distribution of hp
129Xe is notably heterogeneous in the OVA challenged
lungs even at baseline compared with the control lungs
despite comparable inhalation volumes (Table 1). The
mean lung SNR value is higher, although nonsignifi-
cantly different, in the control lungs versus the OVA
treated group (76.6622.1 versus 51.76 9.4, P¼ 0.15).
Volume and distribution of hp 129Xe appears largely
unchanged after a 4.5-mL bolus of Hartmann’s, although
small changes became visible after the initial deliveries
of fluid to the pulmonary circulation in OVA.1 (Fig. 3b)
and control lung C.3. On increasing doses of MCh the
presence of ventilation defects was noticeable in one
control lung after 200 mg of MCh (460 mg cumulative
MCh dose), one 250-mg OVA challenged lung after 100–
200 mg of MCh (260- to 460-mg cumulative MCh dose),
and in two 500-mg OVA challenged lungs after 50–75 mg
of MCh (85- to 160-mg cumulative MCh dose). However,
there were significant reductions in the overall signal
intensities in all OVA challenged lungs compared with
control lungs (mean whole lung SNR at 860-mg cumula-
tive MCh dose for the control lungs¼70.96 28.0 versus
18.26 1.7 for OVA treated lungs, P¼ 0.03). Some reversal
in the gas volume reduction induced by the MCh chal-
lenge became apparent in the images after varying vol-
umes of Hartmann’s solution and up to 1500 mg of
salbutamol in two control animals (C.1 and C.3) and
three OVA challenged animals (OVA.1, OVA.4, and
OVA.5).
Global Changes in hp 129Xe Inhalation Caused by MCh
Challenges
The normalized global signal intensity, GS, (see Eq. [1])
was obtained from slice selective and nonslice selective
measurements of control and OVA challenged lungs
with the results used for a Bland-Altman plot in Figure
4a. The determined bias was 0.656 2.39% in the con-
trol lung (C.1) and 3.0365.57% in the OVA treated lung
(OVA.1), suggesting little systematic difference between
the techniques. The nonslice selective data were used for
further comparison as this allowed for monitoring
changes in whole lung hp gas inhalation (Figs. 4b–d).
Values of the normalized global signal intensity, GS,
averaged for all lungs in the control and OVA challenge
FIG. 2. Bronchoalveolar lavage (BAL) data. % differential inflammatory cell counts. Data from satellite (histology) group with BAL per-
formed immediately after death. a: Note the statistically (P¼0.03) higher inflammatory cell count in the OVA challenged group (OVA sen-
sitized/OVA challenged) compared with the control group (OVA sensitized/PBS challenged). Similarly note the increased % differential
eosinophil count in the OVA challenged group b: indicating allergic inflammation of the airways was present. Total inflammatory cell
counts with standard deviations (error bars) are calculated from sample sizes n¼3 in both OVA challenged and control groups. The
control BAL % differential cell count is calculated from a sample size n¼2 compared with n¼3 in the OVA challenged group.
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groups are shown in Figure 5 as a function of cumulative
MCh dose. In Figure 5, it can be seen that there is an ini-
tial significant drop in global hp gas inhalation between
a cumulative dose of 10–160 mg MCh in the OVA chal-
lenged lungs followed by a slower reduction up to the
maximum cumulative dose of 860 mg.
The 500-mg OVA challenged group showed a signifi-
cant reduction (P< 0.05) in the normalized global signal
intensity over baseline at cumulative MCh dosages above
460 mg (see Figure 5 for details).
Visualization of Changes in hp 129Xe Inhalation Patterns
Caused by MCh Challenges and Reversal
The hp 129Xe MR images in Figures 6a and 7a provide
some insights into regional inhalation pattern changes;
however, a clearer picture emerges through two methods
of data analysis:
FIG. 3. VFA FLASH image datasets from a) control lung and b) ovalbumin (OVA) treated lung at baseline, on perfusion with Hartmann’s
solution, and on increasing dosages of methacholine (MCh) with subsequent reversal. a: (i) Slice selective and (ii) nonslice selective
image data from control rat C.1. There is a large ventilation defect in right lower lobe seen after 200 mg of MCh (white arrows) with sub-
sequent reversal with salbutamol and Hartmann’s solution. b: (i) Slice selective and (ii) nonslice selective image data from OVA chal-
lenged rat OVA.1. Due to on-going inflammation within the lung there is significant heterogeneity in the hp 129Xe distribution on the
baseline images. A small reduction in signal intensity is seen in the right cranial lobe after flushing with 4.5 mL of Hartmann’s solution.
Noticeable reduction in signal intensity is seen after the 50-mg dose of MCh with further large reductions seen until 400 mg of MCh.
Subsequent reversal with salbutamol and Hartmann’s solution results in a slight increase in the hp 129Xe gas signal in the right cranial
lobe and the upper portion of the left lobe (white arrows). The full image datasets for lung C.1 and OVA.1 with multiple baseline images
and those acquired after each dose of MCh are displayed in the Appendix 1 in the Supporting Information.
i. Maps displaying the absolute intensity difference, DAi
(Eq. [2]), between baseline images and images
acquired on increasing MCh dosages are shown in
Figures 6b and 7b, alongside difference maps
acquired on salbutamol reversal. These maps depict
regional changes in absolute hp 129Xe inhalation that
may be above and below hp 129Xe inhalation in the
baseline image.
ii. Relative intensity difference maps, DRi (Eq. [3]), are
shown in Figures 6c and 7c. Note that DRi can assume
values below negative 100% because baseline image
voxels may have relative intensities above 100% of
the mean value.
Using the absolute intensity difference maps, shown in
Figure 6b, ventilation defects were detected before they
became visually apparent on the spin density VFA
FLASH images in Figure 6a. However, the drop in global
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intensity dominates the absolute intensity difference
maps for the OVA challenged lung in Figure 7b thereby
masking the regional changes in relative hp 129Xe inhala-
tion. The gas redistribution can, in principle, be quanti-
fied using regional analysis of the differences in lung
response between apical and basal lung lobes as reported
in Appendix 3 in the Supporting Information. However,
the regional redistribution of the total gas volume within
the lung becomes visually apparent using the relative
intensity difference maps in Figure 7c.
Figures 8a and 8b depict the absolute and relative
intensity difference maps, respectively, for all control
and 500 mg OVA challenged lungs after a cumulative
MCh dosage of 860 mg. The control lungs C.1 and C.2
show noticeable redistribution of hp gas compared with
the baseline as seen on the absolute and relative inten-
sity difference maps. Control lung C.3, however, also
demonstrates a noticeable drop in the absolute signal
intensities across the image series that is largely due to
FIG. 4. a: Bland-Altman plots comparing nonslice and slice selec-
tive normalized global signal intensity data, GS (Eq. [1]), from the
images in sequences (i) Figure 3a (rat lung C.1) and (ii) Figure 3b
(rat lung OVA.1) normalized to the 1st baseline values in each
image sequence (as all other data in this figure). Dashed grey and
solid purple horizontal lines represent the 95% limits of agreement
and the mean bias, respectively. b: Normalized global signal inten-
sity data from the nonslice selective images of hp 129Xe imaged
control lungs. There is an initial drop in the normalized global sig-
nal intensity from the baseline images to the image after 10 mg of
MCh in lung C.3, with minimal subsequent decreases (or
increases as in the case of C.1) over the sequence. Note that the
data points at 10 and 25 mg of MCh for C.2 were lost. c,d: Simi-
larly acquired data as in (b) with (c) representing data from lungs
challenged with 500 mg of OVA and (d) data from lungs chal-
lenged with 250 mg OVA. Note the marked reduction in normalized
global signal intensity over the sequence of events in the OVA
challenged lungs with a greater reduction in the lungs challenged
with 500 mg of OVA.
FIG. 5. Normalized global signal intensity, GS, averaged over all
control and OVA challenged groups as a function of cumulative
dose of MCh. Values are normalized to the average value calcu-
lated from: the two baseline images, the image after 4.5 mL of
Hartmann’s solution, and the image after 10 mg of MCh (to com-
pensate for the effect of small fluctuations in the SEOP process).
Error bars represent6 standard deviation. Note that no standard
deviations were available for the 250-mg OVA challenged group
and for the first two points of the control group (see text for
detail). A significant difference (p<0.0001) was detected on two-
way ANOVA of the dose responses between control and 500-mg
OVA challenged groups on the dose responses. Significant differ-
ence (* as indicated in figure) in response (p<0.05) measured by
a reduction in the normalized global signal intensity was found on
cumulative MCh dosages above 460 mg for the 500-mg OVA chal-
lenged group (p¼0.048 and p¼0.0015 at 460-mg and 860-mg
cumulative dosages of MCh, respectively).
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the drop seen during initial fluid administration. By
comparison, all the OVA challenged lungs show a
decrease in absolute signal intensities across the series.
Furthermore, as can be taken from the scale in Figure 8b,
the relative intensity differences for the OVA model
lungs increase compared with that of the control lungs.
This increase can be quantified by the standard devia-
tion of the relative intensity difference (sRID) that was
approximately three-fold elevated for the OVA model
compared with sRID of the control lungs due to the
increased heterogeneity of hp 129Xe distribution.
DISCUSSION
Changes in hp 129Xe Inhalation Patterns Detected by Ex
Vivo Hyperpolarized 129Xe MRI
Ex vivo hyperpolarized 129Xe MRI has been shown to
allow for imaging of dynamic changes in hp 129Xe inha-
lation in a rat OVA model of human asthma. The hp gas
inhalation protocol and MCh administration demon-
strated significant bronchoconstriction. The overall
reduction in inhaled hp gas volumes is greater in OVA
treated lungs compared with control lungs as noted by
the decrease in global signal intensity, GS, (P¼0.03).
With an observed >50% reduction in whole lung signal
intensities (approximating to a 50% reduction in inhaled
gas volumes), these data may, therefore, have relevance
in severe to life-threatening asthma. Reversal was not
noticeable in measurements of the normalized global sig-
nal intensity, GS, (Eq. [1]); however, reversal affected the
regional gas distribution.
Using the absolute and relative intensity difference
maps, regional gas distribution changes were seen before
they became visually apparent on hp 129Xe spin density
images. While the absolute intensity difference maps of
the OVA treated lungs are dominated by the drop in
global signal intensity, GS, the maps of relative intensity
difference, as defined by Eq. [3], reveal the underlying
changes regional hp 129Xe inhalation (Fig. 7c). Further-
more, an approximately three-fold increased standard
deviation of the relative intensity difference, sRID, in the
OVA model lungs (Fig. 8b) reveals an increase in the
FIG. 6. Image dataset from a control lung (C.1) with accompanying maps displaying changes in regional hp 129Xe distribution. a: Non-
slice selective VFA FLASH image data from lung C.1 on cumulative dosages of MCh as indicated and on reversal with salbutamol and
Hartmann’s solution as displayed in Figure 3a–ii). b: Absolute intensity difference maps with difference between baseline image and
increasing dosages of MCh and on reversal. Red indicates an increase in absolute hp gas signal intensity while blue indicates a reduc-
tion. c: Relative intensity difference maps (see Eq. [3]) indicating regional deviation of the inhaled gas between MCh challenge and base-
line. Green indicates an increase in the regional share of inhaled gas with magenta a decrease compared with the global average. Note
the reduction in the hp 129Xe distribution seen on the difference maps at the right caudal lobe (arrow) where there is a progressive
reduction in signal intensity and the fraction of inhaled hp gas until it becomes visually apparent on the spin density VFA FLASH image
in (a). Other lung regions show an increase in signal intensity and fractional hp gas inhalation. This basal region then permits hp gas
entry on reversal with other lung regions demonstrating a reduction in signal intensity and fraction of inhaled gas. The full set of absolute
intensity difference and relative intensity difference maps in lung C.1 after each dose of MCh are displayed in Appendix 2 in the Sup-
porting Information.
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regional heterogeneity of the hp 129Xe inhalation (rela-
tive to GS) compared with the control lungs. Note that
this work builds on testing of the ex vivo delivery proto-
col in otherwise unrelated studies (see Appendix 4 in
the Supporting Information for an example) where it was
ensured that repeated inflation and deflation of the rat
lung after transport on the times scales indicated (over 5
hours) would not affect results or significantly impact on
regional hp 129Xe inhalation patterns.
Chen et al. have previously studied the effect of high
doses of intravenous (i.v.) MCh (30 mg) on healthy
Sprague-Dawley rats using hp 3He MRI (24). It was
hypothesized that there was a partitioning in the lung
response where gas destined for lung regions with signif-
icant constriction was diverted to less constricted zones,
with associated hyperinflation. The regional data con-
tained within this work confirms this result where gas is
seen to be increasingly diverted to less constricted
regions during rising dosages of MCh. However, unlike
in the live animal where the total dose of MCh is limited
due to systemic concerns, much higher dosages can be
administered repeatedly in the ex vivo model (24). Ex
vivo hp 129Xe MR imaging in the current work was
performed using constant pressure inhalation, similar to
in vivo work by other groups (27), as this was found to
be most sensitive to changes in hp gas inhalation and
with less chance of lung rupture.
Note that image registration methods were not used in
the current proof of principle work and, therefore, arti-
facts, particularly noticeable in airways and at the edge of
lung fields, did occur. In earlier work, Driehuys et al dem-
onstrated regional hp 3He MRI measurements of the lung
parenchyma and on the major airways (55). This enabled
a simple pixel counting method to quantify variation in
localized responses between the two tissues in OVA chal-
lenged mice post MCh. The hp 3He signal intensity from
a volume within the trachea was used by Mistry et al (52)
for normalization of each voxel value. Images were
thereby less dependent on total image signal intensity and
difference maps, generated between baseline images and
on increasing dosages of MCh, enabled visualization of
regions with reductions or increases in hp gas distribu-
tion. Furthermore, quantification of changes in airway
diameters was also possible. However, changes in tracheal
diameter my cause problems for usage of tracheal signal
intensity for image normalization, while in the current
FIG. 7. Image data from an OVA challenged lung (OVA.1) with accompanying maps displaying changes in regional hp 129Xe distribution.
a: Nonslice selective VFA FLASH image data from lung OVA.1 on cumulative dosages of MCh (indicated) and on reversal with salbuta-
mol and Hartmann’s solution as displayed in Fig. 3b-ii). b: Absolute intensity difference maps and (c) relative intensity difference maps
indicating regional deviation of the inhaled gas from the mean inhalation as described in Figure 6 (Eq. [3]). Note the largely global reduc-
tion in the hp 129Xe inhalation seen on the absolute intensity difference maps across the whole lung on increasing MCh dosages, with
small regions of increased signal intensity at the base of the lung and both apices. However, comparing the changes of the relative hp
gas signal in (c) it is clear that these regions (arrows) experience a smaller reduction as compared with other lung regions, with a larger
fraction of the global volume being contained within these regions. On reversal, hp gas distribution shows a global increase with frac-
tional changes in hp 129Xe inhalation that are the opposite of that seen during the MCh challenges. The full set of absolute intensity dif-
ference maps and relative difference maps in lung OVA.1 after each dose of MCh are displayed in Appendix 2 in the Supporting
Information.
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work normalization was performed to the less variable
total signal intensity (Eq. [3]).
Deninger et al described the concept of “fractional ven-
tilation”, defined as the volume of “new” (hyperpolarized)
gas that replaces “old” (nonhyperpolarized) gas on subse-
quent ventilations (56). This concept was subsequently
applied to an Aspergillus fumigatus mouse model of
asthma (25) demonstrating a significant reduction in frac-
tional ventilation values across asthmatic mouse lungs
with considerable heterogeneity between different lung
regions (27,57). Fractional ventilation was not used for the
ex vivo model reported in this proof of concept work that
used a single breath-hold without data averaging; however,
the ex vivo concept could easily be extended to accommo-
date fractional ventilation studies if so desired.
Ex vivo whole lung models have been studied for sev-
eral years. Initially, these measurements were limited to
studies of ventilation parameters in healthy lung tissue
(32,58–60). Later developments using more sophisticated
models studied dynamic ventilatory changes in healthy
rodent lungs (34,42). There are several similarities of the
experimental setup contained within this work, including
the use of a negative pressure differential upon the venti-
lation chamber that acts as artificial pleural cavity to ena-
ble “active” inhalation and the delivery of physiological
perfusate and bronchoactive substances by means of the
pulmonary circulation. Necessary simplifications were,
however, required to allow for hp 129Xe MRI including
the absence of recirculation of warmed perfusate. Further-
more, like other ex vivo whole lung models, it should be
noted that the artificial pleural cavity is usually an arbi-
trary shape, such as a cylinder in the case of this work,
which may result in some nonphysiological lung deforma-
tion and gas redistribution.
Previously, it has been noted that lung responses using
healthy excised ventilated and perfused mouse lungs have
closely matched those seen using PCLS models (34). How-
ever, several groups have found it difficult to detect differ-
ences in AHR between control and OVA treated small
animal lung tissue using PCLS methods (28,61). Whether
this is due to low numbers of large airways included in
each lung slice, the absence of other lung related changes
such as increased airway resistance or possibly the techni-
cal issues surrounding the nonphysiological delivery of
bronchoprovocative compounds is unknown. Furthermore,
an important role for the circulatory system in the devel-
opment of AHR has been described (62). The absence of
the circulatory system in PCLS models may help explain
why differences in AHR have not been detected using this
model. It should be noted that use of whole ex vivo lungs
suffers from none of these limitations.
As some final considerations, it should be noted that sig-
nificant differences in AHR to MCh were detected between
control and OVA lungs using relatively low numbers of
animals (n¼ 3 group sizes in this work) as compared to
other previously reported in vivo plethysmographic (21)
and hp 129Xe methods (26). Although the necessity for ani-
mal culling to perform the ex vivo experiments precludes
longitudinal studies, it is possible that this methodology
could reduce animal numbers if serial measurements are
not required. Furthermore, animal suffering with the ex
vivo model could potentially be further reduced by using
healthy ex vivo lungs treated with sera from small num-
bers of separately sensitized animals (63), allowing for
FIG. 8. Absolute and relative intensity difference maps acquired from all imaged control and 500-mg OVA challenged lungs. Columns
contain difference maps from the same lung as indicated in the figure. (a) Absolute intensity difference map and (b) map indicating the
regional deviation in hp gas volume from the mean of value after 860-mg cumulative dosage MCh as seen in Figures 6 and 7. There is a
global reduction in absolute signal intensity seen in C.3 and all the OVA challenged lungs after 860 mg of MCh with a notable reduction
in voxel signal intensities quantified by the “mean difference”, i.e., the mean over all voxel values of absolute intensity difference (a). The
hp gas is, however, seen to redistribute between different lung regions as seen on the maps in (b) with all lungs (control and OVA) dis-
playing a large distribution of regional responses as indicated by the wide standard deviations of the relative intensity differences (sRID),
greater in the OVA treated lungs. Note the regions of interest (dashed square boxes) indicating locations selected for comparison of
regional lung responses in Appendix 3 in the Supporting Material.
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rapid model generation and throughput investigation
which is not possible using in vivo methods.
CONCLUSIONS
This is the first work investigating a whole organ ex vivo
animal model of the airway hyper-responsiveness found
in human asthma using hp 129Xe MRI methodology.
Changes in both whole lung and regional measurements
of hp 129Xe inhalation were detected, demonstrating sig-
nificant differences in the normalized global signal
intensities between control and OVA challenged animals
using small sample sizes (P< 0.05). OVA models were
affected by reduced overall hp 129Xe inhalation at small
MCh dosages that was not observed in control lungs.
However, control lungs exhibited localized alterations in
the regional gas distribution, visible in absolute intensity
difference maps that may be caused by the diversion of
gas between different lung regions. Relative intensity dif-
ference maps revealed that regional heterogeneity was
also present in the inhalation patterns seen in the OVA
sensitized lungs after MCh challenge and the relative
heterogeneity in the OVA model, quantified by the
standard deviation of the relative intensity differences
(sRID), was increased by a factor of 3 compared with the
control. The relatively straightforward ex vivo hp noble
gas imaging arrangement and the image analysis method-
ology may be useful as an adjunct to current investiga-
tional techniques and may further encourage the use of
ex vivo lung tissue.
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APPENDIX 1. Complete image datasets demonstrating dynamic changes
in hp 129Xe gas distribution on increasing dosages of methacholine (MCh).
APPENDIX 2. Complete dataset demonstrating changes in regional hp
129Xe distribution on increasing dosages of methacholine.
APPENDIX 3. Quantification of changes in hp 129Xe gas distribution on
increasing dosages MCh from selected lung regions.
APPENDIX 4. Example data demonstrating changes in hp 129Xe gas distri-
bution during repeated inhalations over a similar time course.
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